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Early infection is a recognised complication after lung transplantation in patients with cystic fibrosis (CF). Our centre uses multiple
combination bactericidal testing (MCBT) when determining appropriate peritransplant prophylactic regimens. To evaluate our
strategy, we compared the incidence of posttransplant infection in patients whose peritransplant antimicrobial regimens were
determined using MCBT versus standard sensitivity testing. Patients with CF who were infected with Pseudomonas aeruginosa
and underwent lung transplantations between 2000 and 2010 were included. Data was collected from clinical records and our
microbiology database. Microorganisms cultured were mapped against antibiotic resistance, method of sensitivity testing, and
antibiotics administered peritransplant. 129 patients were identified (mean age 28, male : female, 63 : 66). Fifty patients (38.8%)
had antibiotics determined by MCBT. Two patients in the MCBT group developed septicaemia, 13 in the conventional group
(P ≤ 0.05, 2-tailed Fisher’s test). Sepsis was attributable to P. aeruginosa in one patient from the MCBT group and seven patients
in the conventional group (P = 0.15). P. aeruginosa was recovered from the posttransplant pleural fluid of one patient who
received MCBT-guided prophylaxis, six patients in the conventional group (P = 0.25). Patients given antibiotics based on MCBT
had significantly lower rates of septicaemia and lower rates of empyema.
1. Introduction
Lung transplantation is an established therapeutic option
for patients with advanced cystic fibrosis (CF) [1]. The
success of the first transplant for a patient with CF in
1983 [2] spurred further refinement of the management and
selection criteria of patients, leading to significant survival
benefit [3]. However, patients with advanced CF present a
unique microbiological challenge, with disease characterised
by bronchiectasis, severe airflow obstruction, high bacterial
loads, and recurrent lower respiratory tract infections [4–
6]. Unsurprisingly, some centres turn down patients on the
basis of colonisation with multiresistant bacteria. The most
common respiratory pathogen that colonises patients with
CF is Pseudomonas aeruginosa, with up to 80% of patients
being culture-positive for this organism [7]. As the presence
of this microorganism has negative prognostic implications
[8], it is disturbing to note that levels of resistance to frontline
antipseudomonal agents are very high [9].
The presence of multi- and pan-resistant P. aeruginosa
renders methods of single-agent antibiotic susceptibility test-
ing suboptimal [10]. The conventional manner of managing
patients who are colonised with these microorganisms is
to empirically treat them with combinations of antibiotics
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in the peritransplant period. Unfortunately, an empirical
approachmight lead to inadequate bactericidal levels and the
prescription of antibiotics that antagonise each other [11].
This approach is undesirable, as patients with pan-resistant
bacteria have shorter follow-up periods and decreased
survival rates after transplant [12].
An alternative approach is to utilise Multiple Combi-
nation Bactericidal Testing (MCBT), a technique that had
previously been used to systematically test bacterial isolates
against multiple combinations of antibiotics to determine
susceptibility patterns and identify optimal combinations
for potential treatment [13]. Previous studies have demon-
strated that using combinations of antimicrobials may
generate higher levels of in vitro bactericidal activity against
P. aeruginosa [13] and Burkholderia cepacia complex [14].
Our centre currently advocates the use of MCBT (with
modified antimicrobial concentrations) to determine appro-
priate prophylactic regimens in patients about to undergo
lung transplantation for CF and other lung pathologies
that are colonised with antibiotic-resistant Gram-negative
bacteria. To evaluate the effectiveness of our strategy, we
undertook a retrospective analysis to compare the rates of
posttransplant infection in patients whose peritransplant
antimicrobial regimens were determined using the MCBT
versus those who had their antibiotics chosen via conven-
tional sensitivity testing.
2. Methods
2.1. Case Review. We performed a retrospective analysis
of all patients who underwent lung transplantation for
CF between January 2000 and August 2010. Patients were
included in the review if they were colonized pretransplant
with P. aeruginosa (as demonstrated by sequential sputum
cultures) and were excluded if they were colonized with
B. cepacia complex. Data was collected from patients’ case
notes and clinical charts; looking specifically at incidences of
septicaemia at 30 days, posttransplant wound infection at 30
days, empyema at 30 days, all-cause mortality at 30 days, and
all-cause mortality at one year. These were mapped against
antibiotic resistance, method of sensitivity testing, and choice
of antibiotics that were administered. Statistical differences
were calculated using two-tailed Fisher’s test.
2.2. Infection Definitions. Our microbiology database was
interrogated to identify microorganisms cultured from these
patients. Infections were defined by combining positive lab-
oratory culture from tissue source (blood, surgical wound,
and pleural fluid) with at least two of the following four
parameters:
(i) tachycardia (heart rate >90 beats per minute),
(ii) hypotension (systolic blood pressure <90mmHg),
(iii) body temperature <36 ◦C or >38 ◦C,
(iv) abnormal inflammatory markers (white cell count <
4×109 cells/L or > 12×109 cells/L, C-reactive protein
>10mg/L).
2.3. Multiple-Combination Bactericidal Testing. Prior to
2001, prophylactic antimicrobials were chosen based on disc
susceptibility testing using British Society for Antimicrobial
Chemotherapy (BSAC) breakpoints [15]. If sputum was
culture positive for pan-resistant P. aeruginosa or recent
culture results were unavailable, patients were treated empir-
ically with aztreonam, an antistaphylococcal agent (either
flucloxacillin or clindamycin), and metronidazole. Patients
who did not receive peritransplant antibiotics chosen via
the MCBT method were deemed to have received antibi-
otics using “conventional” means. Patients in both MCBT
and conventional groups had antibiotics commenced at
induction. Perioperative antibiotics were continued until the
patient was extubated and could demonstrate a good cough,
(two-three days) to a maximum of seven days.
We introduced the MCBT at our centre in 2001. This was
used in conjunction with conventional means of choosing
peritransplant antibiotics, but, since 2008, MCBT became
the default method for the determination of bactericidal
agents for all patients colonised with antibiotic-resistant
Gram-negative nonfermenters. Bactericidal activity was
determined by testing at least 12 antimicrobials individually
and in combination with each other, leading to 66 different
combinations. Several morphotypes of P. aeruginosa from at
least two pretransplant sputa were selected for testing.
Each antimicrobial or combination of antimicrobials
was tested in IsoSensitest broth using systemic breakpoint
concentrations as specified by the BSAC. After 48 hours
incubation at 37◦C, the turbidity of each broth was measured
at 620 nm. Broths without detectable bacterial growth were
subcultured onto blood agar to calculate 99.9% bacterial
kill [13]. Peritransplant antibiotic regimens were then cho-
sen based on MCBT results and patients’ allergy history.
Any other Gram-negative species (including nonfermenters
and/or Enterobacteriaceae) that may have isolated alongside
P. aeruginosa were also tested using theMCBT, and antibiotic
cocktails were chosen that showed bactericidal activity
against such mixtures of species.
2.4. Peritransplant Immunosuppression Therapy. Our centre
used a three-day induction protocol with antithymocyte
globulin (titrated by flow cytometric analysis of peripheral
blood T lymphocytes) and intravenous methylprednisolone
at a dose of 2mg/kg. Patients were given triple immuno-
suppression posttransplant (azathioprine, ciclosporin and
prednisolone). Ciclosporin was commenced after transplant
as soon as renal function was deemed satisfactory. Alterna-
tives were used in the context of an international clinical
trial (mycophenolate) or in cases of ciclosporin intolerance
(tacrolimus was used). Up to five days of intravenous
ciclosporin was given in the context of poor ciclosporin
absorption in patients with CF.
3. Results
Between January 27, 2000 and August 23, 2010, 163 lung
transplants were performed on patients with CF. This
number included patients who were previously turned down
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Table 1: Patient characteristics.
Characteristic MCBT Conventional Overall
Total number of
transplants on
patients with cystic
fibrosis
65 98 163
Patients included in
the study
50 79 129
Male : female 23 : 27 40 : 39 63 : 66
Mean age (range) 28.7 (16–53) 27.3 (15–54) 28 (15–54)
Single sequential lung
transplant
49 78 127
Liver-lung transplant 1 0 1
Heart-lung transplant 0 1 1
by other centres on the basis of their microbiology. A total
of 129 patients were colonized with P. aeruginosa and not
colonized with B. cepacia complex. Mean age was 28 years
old. There were 63 male patients and 66 female patients. Fifty
patients were given antibiotics that were chosen based on the
MCBT, and there were 79 patients in the conventional group.
Patient characteristics are listed in Table 1.
Our patients were colonized with strains of P. aeruginosa
with varying degrees of antibiotic resistance. We defined
pan-resistance as resistance to antipseudomonal quinolones,
β-lactams, aminoglycosides, and colomycin. In this cohort,
two patients were colonised with pan-resistant P. aeruginosa.
These organisms were resistant to all single agents tested
but bactericidal combinations with colomycin and another
agent were identified. Multiresistant organisms were defined
as resistant to three out of the four antimicrobial groups.
Seventy-one patients were colonised with multiresistant P.
aeruginosa, and nine patients were colonised with fully
susceptible strains. Forty-seven patients were colonised with
organisms that were resistant to one or two groups of
antimicrobials.
Figure 1 shows the relative rates of infectious complica-
tions after lung transplantation in both groups. Two patients
(4%) who were given antibiotics based on MCBT developed
septicaemia compared to 13 (16.5%) in the conventional
group (P ≤ 0.05). The occurrence of Gram-negative sepsis
was statistically lower in the MCBT group, and P. aeruginosa
was responsible for only one case of septicaemia compared
with seven in the conventional therapy group (see Table 2).
P. aeruginosa was recovered from the posttransplant pleural
fluid of one patient (2%) in the MCBT group, as opposed to
six (7.6%) in the conventional group (P = 0.25). There were
no statistically significant differences in the rates of surgical
wound infection (6% in the MCBT group, 3.8% in the
conventional group). There were no statistically significant
differences in all-cause mortality rate at 30 days, with a
10% mortality rate in the MCBT cohort and 6.33% in the
conventional group. This lack of statistical significance was
replicated in all-cause mortality rate at one year (22% in the
MCBT group, 19% in the conventional group).
Septicaemia
18
16
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12
10
8
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2
0
(%
)
Culture-positive
pleural fluid
Surgical wound
infection
Figure 1: Proportion (%) of patients with infectious complications
(at 30 days) after lung transplantation. Black bars: MCBT group.
Grey bars: conventional therapy group.
Table 2: Causes of post-lung-transplant sepsis.
Conventional group
(n = 79)
MCBT group
(n = 50) P
Total cases of sepsis 13a 2b 0.046
Gram-negative sepsis 10 1 0.049
P. aeruginosa sepsis 7 1 0.15
Gram-positive sepsis 3 1 1.0
a
P. aeruginosa (n = 7), Serratia marcescens (n = 2), Achromobacter
xylosoxidans (n = 1), Enterococcus spp. (n = 2), Candida glabrata (n = 1).
bP. aeruginosa (n = 1), Staphylococcus aureus (n = 1).
4. Discussion
Lung transplantation for CF accounts for approximately one-
third of all single sequential lung transplants performed
at our centre [16]. The complex microbiology involved in
this cohort of patients may lead to anxiety when listing
patients with multi- and pan-resistant P. aeruginosa, but this
paper demonstrates for the first time that the MCBT may
have a significant role in altering posttransplant infective
complications for patients with CF. The data indicates that
whilst there may not be evidence for an effect on all-
cause mortality, patients who had antibiotics chosen using
MCBT had lower rates of morbidity. The presence of pleural
infection and septicaemia not only negatively impacts the
patients’ transplant journey but prolongs the hospital length-
of-stay and adds substantial economic burden [17].
We had excluded patients who were colonised with
B. cepacia complex for the purposes of this retrospective
analysis. This is due to the tendency of these patients to
succumb to overwhelming sepsis with one-year mortality
rates of between 50% and 100% [18, 19]. Our group had also
previously noted that infection with Burkholderia cenocepa-
cia in particular led to even poorer mortality outcomes [20].
Unfortunately, we were unable to look at exact causes
of death (septicaemia in particular) in our patient cohort as
causes of death were not readily identifiable in all cases. This
is a reflection of the wide geographical referral area that is
covered by our centre as well as the degree of shared care with
referring centres (covering the north of England, Scotland,
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Northern Ireland, and the Republic of Ireland). A previous
analysis of all patients who underwent lung transplantation
for CF at our centre [16] had identified sepsis as the cause
of death in 18 cases (26% of all recorded CF transplantation
recipient deaths). B. cepacia complex was implicated in
seven of these cases. In an additional three cases, clinical
sepsis was recognised without identification of an underlying
pathogen. Prospective studies would play an important role
in determining if the use of MCBT can significantly decrease
the rate of early mortality due to septicaemia.
Aaron et al. had compared the efficacy of using antimi-
crobial combinations derived fromMCBTwith those derived
from conventional susceptibility testing for treatment of
acute pulmonary exacerbations of CF. They concluded that
regimens based on MCBT results did not result in a better
clinical or bacteriological outcome [21]. It is difficult to
make comparisons between our findings and theirs for both
clinical and technical reasons. On the clinical side, the
patient populations (post-lung-transplant CF versus non-
lung-transplant CF) and outcome measures were different.
There are also major differences in the antimicrobial con-
centrations used in our modified MCBT test and the test as
originally described [13, 14].
In our study, systemic breakpoint concentrations spec-
ified by the BSAC to define susceptibility were used in a
modified MCBT whereas antimicrobial concentrations in
the original MCBT “were chosen on the basis of published
estimates of the average peak levels seen in serum after
standard single-dose intravenous administration” [13]. As a
result, the antimicrobial concentrations used in ourmodified
MCBT were typically two- to eightfold lower than those
previously described [14]. As a consequence, fewer isolates
would be likely to be classified as susceptible in our study.
Table 3 shows the antimicrobials used in this study with their
corresponding concentrations. It also compares these with
those chosen by Aaron et al. [14]. It is impossible to conclude
whether the use of lower breakpoint concentrations of
antimicrobials would have led to more favourable outcomes
in the study of Aaron et al. [21].
As this is a retrospective study, we readily acknowledge
that there are inherent limitations to our findings. The ten-
year period covered by the study has seen numerous changes
with regards to developments in lung transplantation.
These include changes in immunosuppression regimen
and the natural progression with regards to peritransplant
management as the members of our centre gain more
experience. Given the nonrandomized nature of this study
and temporal confounding factors, we cannot definitely
conclude that MCBT should be given at induction to
all patients colonized with P. aeruginosa. However, the
fact that we are dealing with a unique cohort of patients
with significant microbiological challenges might render
it unethical to conduct a full randomized control trial.
Furthermore, it is unlikely that sufficient numbers are
recruited to adequately power such a study.
The data presented is the first indication that patients
given antibiotics based on MCBT results had significantly
lower rates of septicaemia and lower rates of positive
microbiological cultures in their pleural effusions. This is an
Table 3: Antimicrobial agents and breakpoint concentrations
(mg/L) used in the Multiple Combination Bactericidal Test.
Antibiotic
Modified MCBT
using BSAC
breakpoints
Original
MCBT study
Aaron et al.
[14]
Amikacin NT 32
Aztreonam 8 32
Colomycin 4 NT
Ceftazidime 8 32
Chloramphenicol 8 20
Trimethoprim-sulfamethoxazole 10/2 10/2
Ciprofloxacin 1 2
Doripenem 8 NT
Fosfomycin 64 NT
Imipenem NT 10
Meropenem 4 32
Minocycline NT 2
Piperacillin-tazobactam 16/2 32/4
Ticarcillin-clavulanate 16/1 32/10
Temocillin 8 NT
encouraging finding, lending credence to the need for multi-
centre prospective studies to be performed that will ideally
lead to no patients being turned down for a lung transplant
on the basis of colonisation with resistant microorganisms.
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